On June 1st, TIF representatives, Dr Androulla Eleftheriou and Dr Michael Angastiniotis and Mr Loris Brunetta, Board Member, had a fruitful discussion with patient advocates from the AMRO region about the pandemic’s situation reports and challenges related to individuals with thalassaemia in these areas.
EdiGene Application of CRISPR/Cas 9 Gene-editing Therapy ET-01 For β-Thalassaemia Has Been Accepted For Review
octobre 27, 2020
TIF leads the way in creating a Community Advisory Board (CAB) in Europe for thalassaemia and sickle cell disease
mars 26, 2019
août 3, 2020
septembre 12, 2020